• About Us
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Focus Areas
    • Collaborations
  • Our Science
    • Our Pipeline
    • QLS-111
    • Publications & Posters
  • News & Events
  • Careers
  • Contact Us
  • Skip to main content
Qlaris Bio

Qlaris Bio

Careers Contact Us
Our Science

Our Science

Intraocular pressure is comprised of four distinct components that, combined, lead to total intraocular pressure (IOP). These four components are currently best described by the modified Goldmann equation, which includes contributions from the Aqueous Humor Inflow Rate (Q), Uveoscleral Outflow Rate (U), Conventional Outflow Facility (C), and Episcleral Venous Pressure (EVP). EVP is the largest component of IOP, contributing around 2/3 of total IOP. However, no approved therapy to date selectively targets EVP.

Modified Goldmann Equation for IOP

Aqueous Humor Inflow Rate

Beta Blockers:
  • Timolol
  • Betaxolol
  • Levobunolol
  • Metipranolol
Alpha Agonists:
  • Brimonidine
  • Apraclonidine
Carbonic Anhydrase Inhibitors:
  • Brinzolamide
  • Dorzolamide
  • Acetazolamide
  • Methazolamide

Uveoscleral Outflow Rate

Prostaglandin Analogs:
  • Latanoprost
  • Bimatoprost
  • Travaprost
  • Tafluprost
  • Latanoprostene bunod
Alpha Agonists:
  • Brimonidine
  • Apraclonidine

Conventional Trabecular Outflow Facility

Cholinergics (Miotics):
  • Pilocarpine
  • Carbachol
Rho Kinase Inhibitors:
  • Netarsudil

Episcleral Venous Pressure

Selectively targeted by QLS-111

Our Pipeline

Discovery Pre-clinical IND-Enabling Phase 1 Phase 2 Phase 3 Approval
QLS-111POAG/OHT
IND-Enabling
QLS-111NTG
IND-Enabling

QLS-111

QLS-111 is our lead program based upon research from the laboratory of Professor Michael Fautsch at Mayo Clinic.

QLS-111, a novel formulation utilizing our ATP-sensitive potassium (KATP) channel modulator platform, lowers intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the Trabecular Meshwork, thereby reducing distal outflow resistance and lowering Episcleral Venous Pressure (EVP).

Though multiple mechanisms of action exist to lower IOP in patients with glaucoma, these agents target only 3 of the 4 components of IOP as described by the Goldmann equation for IOP: the Aqueous Humor Inflow Rate (Q), Uveoscleral Outflow Rate (U), or Conventional Outflow Facility (C). There are currently no approved drugs that selectively target the reduction of EVP. This leaves a significant gap in the potential to maximally lower IOP since EVP can be the largest determinant of overall IOP.

Studies have demonstrated that treatment with QLS-111 provides persistent IOP lowering, maintains normal vascular integrity of the venous system, and does not cause hyperemia.

Clinical Trials

QLS-101 in Primary Open Angle Glaucoma and Ocular Hypertension

Learn More

QLS-101 in Normal Tension Glaucoma

Learn More

QLS-101 in Adults with Sturge-weber Syndrome

Learn More

Publications & Posters See All Publications & Posters

No posts.

Qlaris Bio, Inc. © 2023 All Rights Reserved Privacy Policy | Terms of Use | Accessibility Statement